Details for New Drug Application (NDA): 018965
✉ Email this page to a colleague
The generic ingredient in NAPROSYN is naproxen. There are forty-two drug master file entries for this compound. Fifty-seven suppliers are listed for this compound. Additional details are available on the naproxen profile page.
Summary for 018965
Tradename: | NAPROSYN |
Applicant: | Atnahs Pharma Us |
Ingredient: | naproxen |
Patents: | 0 |
Pharmacology for NDA: 018965
Mechanism of Action | Cyclooxygenase Inhibitors |
Medical Subject Heading (MeSH) Categories for 018965
Suppliers and Packaging for NDA: 018965
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
NAPROSYN | naproxen | SUSPENSION;ORAL | 018965 | NDA AUTHORIZED GENERIC | Acella Pharmaceuticals, LLC | 42192-619 | 42192-619-16 | 473 mL in 1 BOTTLE (42192-619-16) |
NAPROSYN | naproxen | SUSPENSION;ORAL | 018965 | NDA | Athena Bioscience, LLC | 71511-701 | 71511-701-16 | 473 mL in 1 BOTTLE, PLASTIC (71511-701-16) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION;ORAL | Strength | 25MG/ML | ||||
Approval Date: | Mar 23, 1987 | TE: | AB | RLD: | Yes |
Expired US Patents for NDA 018965
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Atnahs Pharma Us | NAPROSYN | naproxen | SUSPENSION;ORAL | 018965-001 | Mar 23, 1987 | 3,904,682 | ⤷ Subscribe |
Atnahs Pharma Us | NAPROSYN | naproxen | SUSPENSION;ORAL | 018965-001 | Mar 23, 1987 | 4,009,197 | ⤷ Subscribe |
Atnahs Pharma Us | NAPROSYN | naproxen | SUSPENSION;ORAL | 018965-001 | Mar 23, 1987 | 4,001,301 | ⤷ Subscribe |
Atnahs Pharma Us | NAPROSYN | naproxen | SUSPENSION;ORAL | 018965-001 | Mar 23, 1987 | 3,998,966 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription